Hypogammaglobulinemia following COVID-19 infection in a patient on maintenance rituximab

Hypogammaglobulinemia is a known side-effect of rituximab use. It is typically asymptomatic and transient, although certain factors, such as maintenance dosing and concomitant glucocorticoid use can lead to symptomatic or prolonged hypogammaglobulinemia. Patients with symptomatic hypogammaglobulinem...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Bryan, Collin, Espinosa, Ronald, Chittivelu, Subramanyam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8679024/
https://www.ncbi.nlm.nih.gov/pubmed/34925841
http://dx.doi.org/10.1177/2050313X211065791
_version_ 1784616427871797248
author O’Bryan, Collin
Espinosa, Ronald
Chittivelu, Subramanyam
author_facet O’Bryan, Collin
Espinosa, Ronald
Chittivelu, Subramanyam
author_sort O’Bryan, Collin
collection PubMed
description Hypogammaglobulinemia is a known side-effect of rituximab use. It is typically asymptomatic and transient, although certain factors, such as maintenance dosing and concomitant glucocorticoid use can lead to symptomatic or prolonged hypogammaglobulinemia. Patients with symptomatic hypogammaglobulinemia leading to recurrent infections may be treated with intravenous immunoglobulin therapy. Herein, we report a case of a 49-year-old male on maintenance rituximab without prior respiratory symptoms with new onset recurrent pneumonia after COVID-19 pneumonia and treatment with glucocorticoids.
format Online
Article
Text
id pubmed-8679024
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-86790242021-12-18 Hypogammaglobulinemia following COVID-19 infection in a patient on maintenance rituximab O’Bryan, Collin Espinosa, Ronald Chittivelu, Subramanyam SAGE Open Med Case Rep Case Report Hypogammaglobulinemia is a known side-effect of rituximab use. It is typically asymptomatic and transient, although certain factors, such as maintenance dosing and concomitant glucocorticoid use can lead to symptomatic or prolonged hypogammaglobulinemia. Patients with symptomatic hypogammaglobulinemia leading to recurrent infections may be treated with intravenous immunoglobulin therapy. Herein, we report a case of a 49-year-old male on maintenance rituximab without prior respiratory symptoms with new onset recurrent pneumonia after COVID-19 pneumonia and treatment with glucocorticoids. SAGE Publications 2021-12-15 /pmc/articles/PMC8679024/ /pubmed/34925841 http://dx.doi.org/10.1177/2050313X211065791 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
O’Bryan, Collin
Espinosa, Ronald
Chittivelu, Subramanyam
Hypogammaglobulinemia following COVID-19 infection in a patient on maintenance rituximab
title Hypogammaglobulinemia following COVID-19 infection in a patient on maintenance rituximab
title_full Hypogammaglobulinemia following COVID-19 infection in a patient on maintenance rituximab
title_fullStr Hypogammaglobulinemia following COVID-19 infection in a patient on maintenance rituximab
title_full_unstemmed Hypogammaglobulinemia following COVID-19 infection in a patient on maintenance rituximab
title_short Hypogammaglobulinemia following COVID-19 infection in a patient on maintenance rituximab
title_sort hypogammaglobulinemia following covid-19 infection in a patient on maintenance rituximab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8679024/
https://www.ncbi.nlm.nih.gov/pubmed/34925841
http://dx.doi.org/10.1177/2050313X211065791
work_keys_str_mv AT obryancollin hypogammaglobulinemiafollowingcovid19infectioninapatientonmaintenancerituximab
AT espinosaronald hypogammaglobulinemiafollowingcovid19infectioninapatientonmaintenancerituximab
AT chittivelusubramanyam hypogammaglobulinemiafollowingcovid19infectioninapatientonmaintenancerituximab

Ejemplares similares